Q3 2024 EPS Estimates for AdaptHealth Corp. Boosted by Analyst (NASDAQ:AHCO)

AdaptHealth Corp. (NASDAQ:AHCO) – Analysts at Leerink Partnrs increased their Q3 2024 earnings per share estimates for AdaptHealth in a research note issued on Wednesday, May 22nd. Leerink Partnrs analyst W. Mayo now forecasts that the company will post earnings of $0.18 per share for the quarter, up from their prior estimate of $0.17. The consensus estimate for AdaptHealth’s current full-year earnings is $0.80 per share. Leerink Partnrs also issued estimates for AdaptHealth’s Q2 2025 earnings at $0.21 EPS, Q3 2025 earnings at $0.22 EPS, Q4 2025 earnings at $0.43 EPS and FY2026 earnings at $1.06 EPS.

AdaptHealth (NASDAQ:AHCO) last posted its earnings results on Tuesday, February 27th. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.44. AdaptHealth had a negative net margin of 21.45% and a positive return on equity of 8.47%. The firm had revenue of $858.23 million during the quarter, compared to the consensus estimate of $825.94 million.

Several other brokerages also recently issued reports on AHCO. Royal Bank of Canada reiterated an “outperform” rating and issued a $13.00 price target on shares of AdaptHealth in a report on Monday, March 4th. UBS Group raised their target price on AdaptHealth from $9.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. Finally, Truist Financial restated a “buy” rating and issued a $13.00 price target on shares of AdaptHealth in a report on Wednesday, May 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $12.42.

AdaptHealth Price Performance

AdaptHealth stock opened at $10.07 on Friday. The firm has a fifty day moving average of $10.18 and a 200-day moving average of $8.75. AdaptHealth has a 52-week low of $6.37 and a 52-week high of $15.37. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 1.48. The firm has a market capitalization of $1.34 billion, a P/E ratio of -1.91, a PEG ratio of 0.69 and a beta of 1.06.

Insider Buying and Selling

In other AdaptHealth news, major shareholder James E. Flynn sold 182,607 shares of AdaptHealth stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $11.02, for a total transaction of $2,012,329.14. Following the sale, the insider now directly owns 11,643,769 shares in the company, valued at approximately $128,314,334.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, major shareholder James E. Flynn sold 52,487 shares of AdaptHealth stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $10.93, for a total value of $573,682.91. Following the completion of the transaction, the insider now directly owns 11,826,376 shares in the company, valued at $129,262,289.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder James E. Flynn sold 182,607 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $11.02, for a total value of $2,012,329.14. Following the completion of the sale, the insider now directly owns 11,643,769 shares of the company’s stock, valued at $128,314,334.38. The disclosure for this sale can be found here. Insiders own 4.43% of the company’s stock.

Institutional Investors Weigh In On AdaptHealth

Institutional investors have recently made changes to their positions in the company. Deerfield Management Company L.P. Series C increased its stake in AdaptHealth by 22.7% during the third quarter. Deerfield Management Company L.P. Series C now owns 13,607,940 shares of the company’s stock valued at $123,832,000 after purchasing an additional 2,513,026 shares during the last quarter. First Eagle Investment Management LLC grew its position in shares of AdaptHealth by 88.7% during the 3rd quarter. First Eagle Investment Management LLC now owns 410,366 shares of the company’s stock valued at $3,734,000 after buying an additional 192,900 shares during the last quarter. Federated Hermes Inc. raised its stake in AdaptHealth by 672.8% during the fourth quarter. Federated Hermes Inc. now owns 705,125 shares of the company’s stock worth $5,140,000 after acquiring an additional 613,882 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in AdaptHealth by 24.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 857,812 shares of the company’s stock worth $7,806,000 after acquiring an additional 170,923 shares during the last quarter. Finally, Dark Forest Capital Management LP acquired a new position in AdaptHealth in the third quarter valued at approximately $809,000. 82.67% of the stock is currently owned by institutional investors.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.